의약품용 젤라틴 시장 : 세계 시장 예측(2026-2032년)

The Pharmaceutical Gelatin Market is projected to grow by USD 1.98 billion at a CAGR of 6.18% by 2032.

Pharmaceutical gelatin is a highly purified, biocompatible excipient used across hard and soft capsules, tablet coating, microencapsulation, hemostatic applications, plasma expanders, wound care matrices, and vaccine stabilization. Its functional value stems from controlled gel strength, viscosity, film-forming capability, thermal reversibility, digestibility, and compatibility with active pharmaceutical ingredients. Demand is shaped by the continued expansion of oral solid dosage forms, nutraceutical capsules, biologics delivery formats, and patient-friendly dosage technologies that require reliable capsule shells and controlled release performance.

The pharmaceutical gelatin landscape is also being influenced by stricter pharmacopeial standards, traceability requirements, allergen and transmissible spongiform encephalopathy controls, and heightened scrutiny of bovine, porcine, and fish-derived raw materials. Manufacturers and pharmaceutical buyers are prioritizing Good Manufacturing Practice compliance, endotoxin control, heavy metal monitoring, microbial safety, halal and kosher certification where applicable, and robust documentation across the supply chain. As drug developers pursue faster formulation cycles and broader geographic registration, pharmaceutical-grade gelatin remains a critical material where quality consistency, regulatory transparency, and supply resilience determine commercial success.

Transformative Shifts in the Pharmaceutical Gelatin Landscape

The pharmaceutical gelatin industry is undergoing a structural shift from commodity excipient procurement toward quality-led, application-specific sourcing. Capsule manufacturers, contract development partners, and pharmaceutical formulators increasingly require gelatin grades tailored to bloom strength, viscosity, color, clarity, dissolution behavior, cross-linking resistance, and compatibility with hygroscopic or oxygen-sensitive ingredients. This is accelerating the use of tighter specification management, enhanced supplier qualification, and formulation support services.

Another transformative shift is the growing focus on raw material provenance and sustainability. Regulatory expectations and end-user preferences are pushing the industry toward full traceability from hide, bone, or fish source to finished excipient. In parallel, gelatin suppliers are strengthening segregation systems for religious, dietary, and regional compliance needs, including bovine, porcine-free, halal, kosher, and fish gelatin options. The industry is also responding to capsule innovation, including enteric-release softgels, moisture-sensitive formulations, and clean-label nutraceutical-pharma convergence. These developments are positioning pharmaceutical gelatin as a strategic excipient rather than a standard input material.

Cumulative Impact of Artificial Intelligence on Pharmaceutical Gelatin

Artificial intelligence is increasingly relevant across pharmaceutical gelatin production, quality assurance, procurement, and formulation development. In manufacturing, AI-enabled process analytics can support tighter control of extraction, filtration, evaporation, sterilization, drying, and milling parameters, helping producers improve batch consistency for bloom strength, viscosity, particle size, moisture, ash, and microbial limits. Predictive maintenance and anomaly detection also support uptime and reduce quality deviations in regulated production environments.

In quality and regulatory functions, machine learning tools can accelerate document review, certificate-of-analysis comparison, deviation trending, supplier risk scoring, and pharmacopoeial compliance monitoring. For formulation scientists, AI can assist in predicting capsule shell behavior, dissolution performance, gelatin cross-linking risk, plasticizer interactions, and stability outcomes under varying humidity and temperature conditions. In supply chain operations, AI-supported demand sensing and risk mapping can improve visibility into animal-origin raw material availability, logistics disruptions, and regulatory restrictions. The cumulative impact is a move toward more data-rich, transparent, and responsive pharmaceutical gelatin operations while maintaining human oversight for GMP decisions, validation, and regulatory accountability.

Key Regional Insights for Pharmaceutical Gelatin

Asia-Pacific is a major growth environment for pharmaceutical gelatin, supported by large-scale capsule manufacturing, expanding generic drug production, strong nutraceutical consumption, and rising investments in pharmaceutical infrastructure across China, India, Japan, South Korea, Australia, and ASEAN economies. The region benefits from established gelatin processing capabilities and high-volume demand for hard capsules and softgels, while regulatory harmonization efforts and export-oriented manufacturing increase the importance of pharmacopeial compliance and traceable raw material sourcing.

North America demonstrates mature demand driven by advanced pharmaceutical manufacturing, dietary supplement innovation, biologics research, and stringent U.S. and Canadian regulatory expectations for excipient quality, animal-origin documentation, and supplier qualification. Latin America is shaped by growing healthcare access, expanding generic medicine consumption, and increasing local production of capsules and nutraceutical dosage forms, with Brazil and Mexico acting as important regional anchors. Europe remains highly quality-driven, with strong emphasis on European Pharmacopoeia compliance, transmissible spongiform encephalopathy risk controls, sustainability documentation, and preference for fully traceable supply chains. The Middle East is influenced by halal-certified pharmaceutical and nutraceutical products, increasing healthcare investment, and import-dependent supply structures, while Africa is gradually expanding its pharmaceutical manufacturing capacity, supported by public health initiatives, essential medicine demand, and regional efforts to improve medicine availability and quality assurance.

Key Group Insights for Pharmaceutical Gelatin

ASEAN markets are increasingly relevant for pharmaceutical gelatin because of expanding pharmaceutical packaging, nutraceutical production, and regional demand for cost-effective oral dosage forms. The group's diverse regulatory environments require suppliers to manage documentation, halal alignment in majority-Muslim markets, and quality consistency for regional and export-oriented manufacturers. GCC countries place a strong emphasis on halal compliance, healthcare system modernization, and pharmaceutical import quality controls, making certified bovine and fish gelatin options important for capsule and medical applications.

The European Union shapes global pharmaceutical gelatin standards through strict excipient regulation, pharmacopoeial alignment, sustainability expectations, and documentation requirements for animal-derived materials. BRICS economies collectively influence demand through large populations, expanding domestic pharmaceutical manufacturing, and policy efforts to improve medicine self-sufficiency, with China, India, Brazil, and South Africa contributing to regionalized supply chain development. G7 countries represent highly regulated, innovation-led consumption environments where gelatin is used in advanced formulations, premium softgels, and medical applications under rigorous quality systems. NATO member economies, particularly those in North America and Europe, add an additional layer of strategic supply chain focus, as pharmaceutical resilience, domestic manufacturing capacity, and secure access to critical excipients become priorities in healthcare preparedness planning.

Key Country Insights for Pharmaceutical Gelatin

The United States is one of the most advanced pharmaceutical gelatin markets, supported by strong demand for prescription capsules, over-the-counter drugs, nutraceutical softgels, and regulated excipient quality systems. Canada follows similar quality expectations, with demand tied to pharmaceuticals, dietary supplements, and health product compliance. Mexico benefits from growing pharmaceutical manufacturing, proximity to North American supply chains, and rising consumption of affordable oral dosage forms. Brazil is a leading Latin American market, supported by domestic medicine production, nutraceutical growth, and expanding healthcare access.

In Europe, the United Kingdom remains important for pharmaceutical innovation, contract development, and high-specification excipient demand. Germany's strength in pharmaceutical manufacturing, medical technology, and quality assurance reinforces demand for tightly controlled gelatin grades. France supports demand through its pharmaceutical, nutraceutical, and cosmetic-health sectors, while Russia's localization policies and domestic drug production initiatives influence gelatin sourcing needs. Italy and Spain contribute through established pharmaceutical production, softgel manufacturing, and nutraceutical consumption.

In Asia-Pacific, China combines large-scale capsule manufacturing, pharmaceutical production, and domestic gelatin processing capabilities, making quality control and export compliance central considerations. India is a major user of pharmaceutical gelatin due to its extensive generic drug and capsule manufacturing base, with rising emphasis on global regulatory compliance. Japan prioritizes high-purity excipients, quality consistency, and advanced dosage technologies, while Australia's demand is supported by complementary medicines, regulated health products, and import quality controls. South Korea is driven by innovative pharmaceuticals, nutraceutical softgels, and advanced manufacturing standards, strengthening demand for reliable pharmaceutical-grade gelatin.

Actionable Recommendations for Pharmaceutical Gelatin Industry Leaders

Industry leaders should prioritize a quality-first gelatin sourcing strategy that aligns technical specifications with end-use performance in capsules, tablets, softgels, hemostats, and controlled-release systems. Supplier qualification should include raw material traceability, GMP alignment, pharmacopeial compliance, microbial and endotoxin controls, transmissible spongiform encephalopathy documentation, halal or kosher certification where relevant, and validated change-control processes.

Manufacturers should invest in digital quality management, AI-enabled process monitoring, and predictive supply chain risk assessment to reduce deviations and improve batch-to-batch consistency. Formulation teams should collaborate earlier with gelatin suppliers to address dissolution, cross-linking, moisture sensitivity, plasticizer compatibility, and stability risks. Procurement leaders should diversify approved sources across bovine, porcine, and fish gelatin where formulation and regulatory requirements allow, while maintaining robust equivalency testing. Companies serving multiple regions should build documentation packages that support U.S., European, Japanese, and emerging-market registration expectations to reduce approval delays and strengthen customer confidence.

Research Methodology for Pharmaceutical Gelatin Insights

The research approach for pharmaceutical gelatin combines secondary research, regulatory review, and primary validation to ensure accuracy and industry relevance. Secondary inputs include pharmacopeial standards, regulatory guidance on pharmaceutical excipients and animal-origin materials, public health agency documents, trade publications, scientific literature, patent activity, dosage form development trends, and documented manufacturing practices. Particular attention is given to gelatin specifications such as bloom strength, viscosity, microbial limits, endotoxin control, moisture, ash, heavy metals, and source-based compliance requirements.

Primary validation typically involves structured discussions with excipient specialists, capsule manufacturers, pharmaceutical formulators, quality assurance professionals, procurement leaders, regulatory affairs experts, and distribution stakeholders. Findings are triangulated across multiple verified sources to identify consistent demand drivers, technology shifts, regulatory priorities, and regional differences. The methodology excludes speculative sizing and forecasting and focuses instead on evidence-backed qualitative insights, supply chain behavior, technical requirements, and strategic implications for pharmaceutical gelatin stakeholders.

Conclusion

Pharmaceutical gelatin continues to play an essential role in modern drug delivery, supported by its versatility, proven safety profile, and functional performance across capsules, softgels, tablets, hemostatic products, and specialized formulations. The industry is becoming more sophisticated as buyers demand greater traceability, tighter quality controls, application-specific functionality, and documentation suitable for global regulatory review.

The next phase of competitive advantage will depend on resilient sourcing, digitalized quality systems, AI-supported process intelligence, and closer collaboration between gelatin suppliers and pharmaceutical developers. Regions and countries with strong regulatory frameworks, manufacturing capacity, and excipient expertise will continue shaping best practices, while emerging markets expand access to gelatin-based dosage forms. For industry participants, success will come from treating pharmaceutical gelatin as a strategic excipient that connects formulation performance, patient acceptability, regulatory compliance, and supply chain reliability.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Pharmaceutical Gelatin Market, by Type

• 7.1. Introduction
• 7.2. Type A
• 7.3. Type B

8. Pharmaceutical Gelatin Market, by Form

• 8.1. Introduction
• 8.2. Powder
• 8.3. Sheet
• 8.4. Granules

9. Pharmaceutical Gelatin Market, by Source

• 9.1. Introduction
• 9.2. Porcine
• 9.3. Bovine Skin
• 9.4. Bovine Bone
• 9.5. Marine
• 9.6. Poultry

10. Pharmaceutical Gelatin Market, by Application

• 10.1. Introduction
• 10.2. Hard Capsule
• 10.3. Absorbable Hemostats
• 10.4. Soft Capsule
• 10.5. Tablet Coating
• 10.6. Wound Dressings

11. Pharmaceutical Gelatin Market, by Distribution Channel

• 11.1. Introduction
• 11.2. Offline
• 11.3. Online

12. Pharmaceutical Gelatin Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Pharmaceutical Gelatin Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Pharmaceutical Gelatin Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. FPNV Positioning Matrix, 2025
• 15.3. Market Concentration Analysis, 2025
  • 15.3.1. Concentration Ratio (CR)
  • 15.3.2. Herfindahl Hirschman Index (HHI)
• 15.4. Recent Developments & Impact Analysis, 2025
• 15.5. Product Portfolio Analysis, 2025
• 15.6. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Baotou Dongbao Bio-Tech Co., Ltd.
• 16.2. Darling Ingredients Inc.
• 16.3. Ewald-Gelatine GmbH
• 16.4. Gelita AG
• 16.5. Gelken Gelatin Co., Ltd.
• 16.6. Gelnex Industria e Comercio Ltda.
• 16.7. Geltech Co., Ltd.
• 16.8. Henan Boom Gelatin Co., Ltd.
• 16.9. India Gelatine & Chemicals Ltd.
• 16.10. ITALGEL S.r.l.
• 16.11. Jiangxi Gelatins Co., Ltd.
• 16.12. Junca Gelatines S.L.
• 16.13. Lapi Gelatine S.p.a.
• 16.14. Nippi Inc.
• 16.15. Nitta Gelatin Inc.
• 16.16. Norland Products Inc.
• 16.17. PB Leiner
• 16.18. Qinghai Gelatin Co., Ltd.
• 16.19. Rousselot S.A.S.
• 16.20. Sterling Biotech Ltd.
• 16.21. Suheung Co., Ltd
• 16.22. Tessenderlo Group NV
• 16.23. Trobas Gelatine BV
• 16.24. Weishardt Group
• 16.25. Xiamen Gelken Gelatin Co., Ltd.